Cardiovascular Systems Sponsoring Lunch Symposium on Arterial Calcium at 2013 VIVA Conference

  Cardiovascular Systems Sponsoring Lunch Symposium on Arterial Calcium at
  2013 VIVA Conference

     Company Also Featuring Hands-on Cadaver Mobile Lab Training Session

Business Wire

ST. PAUL, Minn. -- October 2, 2013

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), is sponsoring a lunch
symposium highlighting the challenges and treatment options for Peripheral
Arterial Disease complicated by calcium at the 2013 Vascular Interventional
Advances (VIVA) conference in Las Vegas, Oct. 8-11, 2013. In order to enhance
this learning opportunity, CSI will also host a hands-on training session in
its mobile lab using cadavers to train attendees on pedal access and the use
of orbital atherectomy.

CSI-Sponsored Lunch Symposium: Oct. 10

WHAT: Industry leaders will share their expertise on issues related to the
treatment of arterial calcium during a lunch symposium sponsored by CSI. The
symposium, titled “Arterial Calcium: Challenges and Treatments,” will cover
the implications of calcium in device selection, treatment options and
outcomes with orbital atherectomy. It will address treatment techniques in
complex cases as well as the limitations and considerations of emerging
drug-coated and bioresorbable platforms. The symposium will be moderated by
John Rundback, MD, Holy Name Medical Center, Teaneck, N.J.

            
        TOPICS:
                  Prevalence of Calcium and Implications for Infrapopliteal
        --        Device Selection – Lawrence Garcia, MD, St. Elizabeth’s
                  Medical Center, Brighton, Mass.
                  Clinical Outcomes of OAS Treatment Options for
        --        Infrapopliteal Patients – John Rundback, MD, Holy Name
                  Medical Center, Teaneck, N.J.
                  Simple Techniques for Complex Cases – Arthur Lee, MD,
        --        Cardiac & Vascular Institute, Lake City Medical Center,
                  North Florida Regional Medical Center, Gainesville, Fla.
                  Limitations of Current Drug Eluting and Bioresorbable
        --        Technologies – Biological Considerations for Future Device
                  Selection – Thomas Zeller, MD, University Heart Center
                  Freiburg-Bad Krozingen, Bad Krozingen, Germany
        --        Panel Discussion
                  
        WHEN:     Thursday, Oct. 10, 12:00 – 1:15 p.m.
                  
        WHERE:    Lafite 7, Wynn Las Vegas
                  3131 Las Vegas Blvd. S.
                  Las Vegas, NV 89109
                  

Mobile Training Lab: Oct. 10

WHAT: CSI will host a cutting-edge, hands-on cadaver lab at VIVA, featuring
ultrasound guided tibial and pedal access followed by orbital atherectomy
treatment.

           
        WHEN:    Thursday, Oct. 10, 5:30 p.m.
                 
        WHERE:   Mouton 2, Wynn Las Vegas
                 3131 Las Vegas Blvd. S.
                 Las Vegas, NV 89109
                 

CSI Booth at VIVA: Oct. 8–10

Visit CSI at booth #406, 7 a.m. – 4:15 p.m., Tuesday, Oct. 8; Wednesday, Oct.
9; and Thursday, Oct. 10.

About Peripheral Arterial Disease (PAD)
PAD is a life-threatening condition where a fatty material called plaque
builds up on the inside walls of the blood vessels that carry blood from the
heart to legs and arms. The plaque buildup causes the arteries to harden and
narrow (atherosclerosis), reducing blood flow to the legs. The risk of PAD
increases if a person has one or several of the following: high blood
pressure, abnormal cholesterol levels, diabetes, or personal history of heart
disease, heart attack or stroke. PAD affects an estimated 8-12 million people
in the United States. The disease prevalence increases with age and 12-20
percent of Americans age 65 and older suffer from PAD symptoms. As the U.S.
population ages, the prevalence range could reach 16 million in those age 65
and older and 19 million overall by 2050.

About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device
company focused on developing and commercializing innovative solutions for
treating vascular and coronary disease. The company’s Orbital Atherectomy
Systems treat calcified and fibrotic plaque in arterial vessels throughout the
leg in a few minutes of treatment time, and address many of the limitations
associated with existing surgical, catheter and pharmacological treatment
alternatives. The U.S. FDA granted 510(k) clearance for the use of the
Diamondback Orbital Atherectomy System in August 2007. To date, nearly 110,000
of CSI’s devices have been sold to leading institutions across the United
States. CSI has also completed its ORBIT II Investigational Device Exemption
clinical trial to evaluate the safety and effectiveness of its orbital
technology in treating coronary arteries. The coronary system is limited by
federal law to investigational use and is currently not commercially available
in the United States.

For more information, visit the company’s website at www.csi360.com.

Contact:

For Cardiovascular Systems, Inc.
Investor Relations, 651-259-2800
investorrelations@csi360.com
or
Sarah Wozniak, 651-259-1636
swozniak@csi360.com
or
PadillaCRT:
Matt Sullivan, 612-455-1709
msullivan@padillacrt.com
or
Dave Folkens, 612-455-1741
dfolkens@padillacrt.com